Stay updated on Acalabrutinib Pembrolizumab Combo in Head & Neck Cancer Clinical Trial

Sign up to get notified when there's something new on the Acalabrutinib Pembrolizumab Combo in Head & Neck Cancer Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Acalabrutinib Pembrolizumab Combo in Head & Neck Cancer Clinical Trial page

  1. Check
    7 days ago
    No Change Detected
  2. Check
    14 days ago
    Change Detected
    Summary
    Added site Revision: v3.4.2. Removed the government funding/operating status notice from the page.
    Difference
    0.5%
    Check dated 2026-02-11T02:18:09.000Z thumbnail image
  3. Check
    21 days ago
    Change Detected
    Summary
    Added a government funding notice and a site revision notice (Revision: v3.4.1); removed the previous revision (v3.4.0). To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.5%
    Check dated 2026-02-04T00:25:26.000Z thumbnail image
  4. Check
    28 days ago
    Change Detected
    Summary
    Show glossary toggle added and minor UI label changes (e.g., capitalization in 'Last Update Submitted that Met QC Criteria' and 'No FEAR Act Data'). The footer revision now shows v3.4.0.
    Difference
    0.2%
    Check dated 2026-01-28T00:22:32.000Z thumbnail image
  5. Check
    42 days ago
    Change Detected
    Summary
    Revision: v3.3.4 is shown, replacing v3.3.3. No user-facing content or study details appear to be affected.
    Difference
    0.1%
    Check dated 2026-01-14T01:28:28.000Z thumbnail image
  6. Check
    64 days ago
    Change Detected
    Summary
    Added a Locations section with Oregon as a study site, updating core participation details. Removed the old Oregon Locations label and the HHS Vulnerability Disclosure link; revision updated to v3.3.3.
    Difference
    0.2%
    Check dated 2025-12-23T08:37:48.000Z thumbnail image
  7. Check
    85 days ago
    Change Detected
    Summary
    Footer revision updated from v3.3.1 to v3.3.2; no study content or navigation changes detected. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.1%
    Check dated 2025-12-01T17:37:08.000Z thumbnail image

Stay in the know with updates to Acalabrutinib Pembrolizumab Combo in Head & Neck Cancer Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Acalabrutinib Pembrolizumab Combo in Head & Neck Cancer Clinical Trial page.